home / stock / adyx / adyx quote
Last: | $ |
---|---|
Change Percent: | 4.88% |
Open: | $1.16 |
Close: | $1.29 |
High: | $1.29 |
Low: | $1.16 |
Volume: | 1,200 |
Last Trade Date Time: | 02/12/2020 04:42:05 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $1.16 | $1.29 | $1.29 | $1.16 | 1,200 | 02-12-2020 |
$ | $1.30 | $1.23 | $1.30 | $1.23 | 1,725 | 02-11-2020 |
$ | $1.26 | $1.26 | $1.26 | $1.26 | 233 | 02-10-2020 |
$ | $N/A | $1.50 | $N/A | $N/A | 33 | 02-07-2020 |
$ | $1.37 | $1.50 | $1.50 | $1.18 | 1,599 | 02-06-2020 |
$ | $1.20 | $1.19 | $1.20 | $1.18 | 936 | 02-05-2020 |
$ | $1.425 | $1.36 | $1.425 | $1.36 | 858 | 02-04-2020 |
$ | $1.35 | $1.40 | $1.44 | $1.35 | 1,026 | 02-03-2020 |
$ | $1.685 | $1.58 | $1.705 | $1.215 | 7,979 | 01-31-2020 |
$ | $1.52 | $1.74 | $1.74 | $1.52 | 6,285 | 01-30-2020 |
$ | $N/A | $1.50 | $N/A | $N/A | 0 | 01-29-2020 |
$ | $1.63 | $1.50 | $1.63 | $1.50 | 417 | 01-28-2020 |
$ | $1.40 | $1.40 | $1.40 | $1.40 | 1,232 | 01-27-2020 |
$ | $1.42 | $1.40 | $1.42 | $1.40 | 312 | 01-24-2020 |
$ | $1.40 | $1.42 | $1.50 | $1.40 | 621 | 01-23-2020 |
$ | $1.64 | $1.64 | $1.64 | $1.64 | 157 | 01-22-2020 |
$ | $1.23 | $1.50 | $1.65 | $1.18 | 4,444 | 01-21-2020 |
$ | $1.55 | $1.60 | $1.60 | $1.55 | 604 | 01-20-2020 |
$ | $1.55 | $1.60 | $1.60 | $1.55 | 604 | 01-17-2020 |
$ | $1.40 | $1.52 | $1.52 | $1.40 | 392 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced fi...
SAN FRANCISCO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced th...
SAN FRANCISCO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced fi...